Publication | Open Access
64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)
34
Citations
0
References
2020
Year
OphthalmologyMedicineMelanomaDermatologyCancer TreatmentOncologyRadiation OncologyMetastatic Uveal MelanomaCancer ResearchMulti-center Study
No additional data available for this publication yet. Check back later!